Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 115

Similar articles for PubMed (Select 23855653)


A prospective, non-randomized, no placebo-controlled, phase Ib clinical trial to study the safety of the adipose derived stromal cells-stromal vascular fraction in idiopathic pulmonary fibrosis.

Tzouvelekis A, Paspaliaris V, Koliakos G, Ntolios P, Bouros E, Oikonomou A, Zissimopoulos A, Boussios N, Dardzinski B, Gritzalis D, Antoniadis A, Froudarakis M, Kolios G, Bouros D.

J Transl Med. 2013 Jul 15;11:171. doi: 10.1186/1479-5876-11-171.


Stem cell therapy for idiopathic pulmonary fibrosis: a protocol proposal.

Tzouvelekis A, Koliakos G, Ntolios P, Baira I, Bouros E, Oikonomou A, Zissimopoulos A, Kolios G, Kakagia D, Paspaliaris V, Kotsianidis I, Froudarakis M, Bouros D.

J Transl Med. 2011 Oct 21;9:182. doi: 10.1186/1479-5876-9-182.


A phase 1b study of placenta-derived mesenchymal stromal cells in patients with idiopathic pulmonary fibrosis.

Chambers DC, Enever D, Ilic N, Sparks L, Whitelaw K, Ayres J, Yerkovich ST, Khalil D, Atkinson KM, Hopkins PM.

Respirology. 2014 Oct;19(7):1013-8. doi: 10.1111/resp.12343. Epub 2014 Jul 9.


Airway clearance devices for cystic fibrosis: an evidence-based analysis.

Health Quality Ontario.

Ont Health Technol Assess Ser. 2009;9(26):1-50. Epub 2009 Nov 1.


Imatinib treatment for idiopathic pulmonary fibrosis: Randomized placebo-controlled trial results.

Daniels CE, Lasky JA, Limper AH, Mieras K, Gabor E, Schroeder DR; Imatinib-IPF Study Investigators.

Am J Respir Crit Care Med. 2010 Mar 15;181(6):604-10. doi: 10.1164/rccm.200906-0964OC. Epub 2009 Dec 10.


BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis.

King TE Jr, Brown KK, Raghu G, du Bois RM, Lynch DA, Martinez F, Valeyre D, Leconte I, Morganti A, Roux S, Behr J.

Am J Respir Crit Care Med. 2011 Jul 1;184(1):92-9. doi: 10.1164/rccm.201011-1874OC. Epub 2011 Apr 7.


A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma.

Hoyles RK, Ellis RW, Wellsbury J, Lees B, Newlands P, Goh NS, Roberts C, Desai S, Herrick AL, McHugh NJ, Foley NM, Pearson SB, Emery P, Veale DJ, Denton CP, Wells AU, Black CM, du Bois RM.

Arthritis Rheum. 2006 Dec;54(12):3962-70.


Safety reporting on implantation of autologous adipose tissue-derived stem cells with platelet-rich plasma into human articular joints.

Pak J, Chang JJ, Lee JH, Lee SH.

BMC Musculoskelet Disord. 2013 Dec 1;14:337. doi: 10.1186/1471-2474-14-337.


Treatment of idiopathic pulmonary fibrosis with etanercept: an exploratory, placebo-controlled trial.

Raghu G, Brown KK, Costabel U, Cottin V, du Bois RM, Lasky JA, Thomeer M, Utz JP, Khandker RK, McDermott L, Fatenejad S.

Am J Respir Crit Care Med. 2008 Nov 1;178(9):948-55. doi: 10.1164/rccm.200709-1446OC. Epub 2008 Jul 31.


A placebo-controlled, randomized trial of mesenchymal stem cells in COPD.

Weiss DJ, Casaburi R, Flannery R, LeRoux-Williams M, Tashkin DP.

Chest. 2013 Jun;143(6):1590-8. doi: 10.1378/chest.12-2094.


Safety of cell therapy with mesenchymal stromal cells (SafeCell): a systematic review and meta-analysis of clinical trials.

Lalu MM, McIntyre L, Pugliese C, Fergusson D, Winston BW, Marshall JC, Granton J, Stewart DJ; Canadian Critical Care Trials Group.

PLoS One. 2012;7(10):e47559. doi: 10.1371/journal.pone.0047559. Epub 2012 Oct 25. Review.


Adipose-derived mesenchymal stromal cells for chronic myocardial ischemia (MyStromalCell Trial): study design.

Qayyum AA, Haack-Sørensen M, Mathiasen AB, Jørgensen E, Ekblond A, Kastrup J.

Regen Med. 2012 May;7(3):421-8. doi: 10.2217/rme.12.17. Review.


Treatment of acute respiratory distress syndrome with allogeneic adipose-derived mesenchymal stem cells: a randomized, placebo-controlled pilot study.

Zheng G, Huang L, Tong H, Shu Q, Hu Y, Ge M, Deng K, Zhang L, Zou B, Cheng B, Xu J.

Respir Res. 2014 Apr 4;15:39. doi: 10.1186/1465-9921-15-39.


Mitoxantrone: a review of its use in multiple sclerosis.

Scott LJ, Figgitt DP.

CNS Drugs. 2004;18(6):379-96. Review.


Expansion of the human adipose-derived stromal vascular cell fraction yields a population of smooth muscle-like cells with markedly distinct phenotypic and functional properties relative to mesenchymal stem cells.

Basu J, Genheimer CW, Guthrie KI, Sangha N, Quinlan SF, Bruce AT, Reavis B, Halberstadt C, Ilagan RM, Ludlow JW.

Tissue Eng Part C Methods. 2011 Aug;17(8):843-60. doi: 10.1089/ten.tec.2010.0697. Epub 2011 May 19.


Changing the idiopathic pulmonary fibrosis treatment approach and improving patient outcomes.

Cottin V.

Eur Respir Rev. 2012 Jun 1;21(124):161-7. doi: 10.1183/09059180.00001112. Review.


Both immediate and delayed intracavernous injection of autologous adipose-derived stromal vascular fraction enhances recovery of erectile function in a rat model of cavernous nerve injury.

Qiu X, Fandel TM, Ferretti L, Albersen M, Orabi H, Zhang H, Lin G, Lin CS, Schroeder T, Lue TF.

Eur Urol. 2012 Oct;62(4):720-7. doi: 10.1016/j.eururo.2012.02.003. Epub 2012 Feb 18. Erratum in: Eur Urol. 2012 Dec;62(6):e106. Orabi, Hazem [added].


Non-expanded adipose stromal vascular fraction cell therapy for multiple sclerosis.

Riordan NH, Ichim TE, Min WP, Wang H, Solano F, Lara F, Alfaro M, Rodriguez JP, Harman RJ, Patel AN, Murphy MP, Lee RR, Minev B.

J Transl Med. 2009 Apr 24;7:29. doi: 10.1186/1479-5876-7-29. Review.


Safety and tolerability of inhaled heparin in idiopathic pulmonary fibrosis.

Markart P, Nass R, Ruppert C, Hundack L, Wygrecka M, Korfei M, Boedeker RH, Staehler G, Kroll H, Scheuch G, Seeger W, Guenther A.

J Aerosol Med Pulm Drug Deliv. 2010 Jun;23(3):161-72. doi: 10.1089/jamp.2009.0780.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk